Erika P. Hamilton, MD

Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses the results from a phase II study of abemaciclib plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.

Hamilton says there are currently not very many "good" drugs for treating these metastases. She adds that the mainstay for treating these metastases is usually some form of radiation therapy, such as whole brain radiation.

Erika P. Hamilton, MD, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer.

Erika P. Hamilton, MD, on ONT-380 for HER2-positive breast cancer and the treatment's ability to cross the blood-brain barrier.

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the challenges associated with utilizing new agents in HER2-positive breast cancer.

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.